Adial Pharmaceuticals Inc
adial.comWhat Do They Do?
Develops an oral, colon-targeted drug candidate for ulcerative colitis and a genetically targeted treatment candidate for alcohol use disorder.
8-K, filed Jun 11, 2026 10-K for FY2025, filed Mar 5, 2026Adial Pharmaceuticals is a biopharmaceutical company historically focused on the development of treatments for addictions and related…View ↗
We are a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 5, 2026
Who Are Their Customers?
For AD04, the company expects addiction specialists to order genetic tests and prescribe the drug to patients who test positive.
10-K for FY2025, filed Mar 5, 2026Summarizing the findings, addiction specialists will order the genetic test for 50% to 100% of their AUD patients. If the genetic test is…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$52MView ↗
- ▲ +2555% (Loss)
- vs −$2M in Q2 FY2025
-
Aug 21, 2026
Nasdaq notified Adial that it fell below the continued-listing equity requirement
The notice did not immediately affect trading; Adial planned to seek approval to convert preferred shares and submit a compliance plan.
Sources
8-K, filed Aug 21, 2026
On August 18, 2026, Adial Pharmaceuticals, Inc. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market (“Nasdaq”)…View ↗
-
Aug 13, 2026
CEO and CFO departures are anticipated if shareholders approve proposals
Matthew Davidson is expected to become CEO, while a new CFO is expected to be appointed after the meeting.
Sources
8-K, filed Aug 13, 2026
As of August 10, 2026, Adial Pharmaceuticals, Inc. (the “Company”) anticipates that the employment of its current President and Chief…View ↗
-
Jun 11, 2026
Adial acquired Azora, adding the AT177 ulcerative-colitis program
AT177 is an oral, colon-targeted candidate; the acquisition also came with an initial private financing tranche.
Sources
8-K, filed Jun 11, 2026
GLEN ALLEN, Va. and LOS ANGELES, Calif., June 11, 2026 — Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today…View ↗
Development focus
The older report described plans to commercialize the lead drug candidate in the U.S. and Europe; the latest report emphasizes completing clinical development for genetically selected patient groups, primarily in the U.S.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 5, 2026We are a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction…View ↗
We are a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction…View ↗
Purnovate removed
The older report described using Purnovate's drug-discovery platform to develop candidates; the latest report says Purnovate's assets and business were sold.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 5, 2026In January 2021, we expanded our portfolio in the field of addiction with the acquisition of Purnovate, LLC via a merger into our wholly…View ↗
Purnovate, LLC, was our wholly owned subsidiary, formed as a Virginia limited liability company in April 2019. Purnovate, LLC converted…View ↗
Loading...
